Skip to main content
letter
. 2022 Dec 22;108(6):1680–1684. doi: 10.3324/haematol.2022.282264

Table 2.

Clinical outcomes based on the frontline regimen used for patients with AL amyloidosis associated with Waldenström macroglobulinemia.

graphic file with name 1081680.tab2.jpg